Filing Date If Appropriate

PTO/SB/08A(04-07)
Modified form approved for use through 09/30/2007, OMB 651-0031
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE

Document

Under the Paperwork Reduction Act or 1995, no persons are required to respond to a collection or information unless it contains a valid Onto Control number				
Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Complete if Known			
	Application Number	10/589,216		
	Filing Date	January 15, 2008		
	First Named Inventor	Lloyd S. Gray		
(Use as many sheets as necessary)	Group Art Unit	1642		
	Examiner Name	Christopher Yaen		
Sheet 1 of 1	Attorney Docket No: 1036.115US1			

US PATENT DOCUMENTS USP Document Number Publication Date Name of Patentee or Applicant of cited

Examine

Initial *

FOREIGN PATENT DOCUMENTS					
Examiner Initial *	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T 1	
	WO-9929847A1	6/17/1999	Perez-Reves, et al.		

	OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS				
Examiner Initial *	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 1			
	"Japanese Application Serial No. 2006-553243, Office Action mailed 08-03-10", 10 pgs				
	BERTOLESI, GABRIEL E., et al., "The Ca2+ Channel Antagonists Mibefradil and Pimozide Inhibit Cell Growth via Different Cytotoxic Mechanisms", Mol. Pharmacol. Vol. 62, No.2, (2002), 210-219				
	HEADY, TIFFANY N., et al., "Molecular Pharmacology of T-type Ca2+ Channels", Jpn. J. Pharmacol Vol. 85, (2001), 339-350				
	YUNKER, A.M. R., et al., "Immunological Characterizations of T-Type Voltage Dependent Calcium Channel CAv3.1 (ALPHA1G) and CAv3.3 (ALPHA1I) Isoforms Reveal Differences in Their Localization, Expression, and Neural Development", Neuroscience Vol. 117, (2003), 321-335				